HERTFORDSHIRE, England and PITTSBURGH, March 29, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), today announced the successful acquisition of the global rights to the Cold-EEZE® brand cold remedy line from ProPhase Labs, Inc.
The transaction provides Mylan all assets and rights relating to the Cold-EEZE® brand, including all U.S. businesses and U.S. and international trademarks. The Cold-EEZE® family of brands includes leading over-the-counter (OTC) cold remedies sold as lozenges, gummies, oral sprays, caplets, QuickMelts® and oral liquid dose forms in the U.S.
Mylan CEO Heather Bresch commented, "The completion of this transaction is an important step as we continue to expand our consumer healthcare offerings. Cold-EEZE® is now Mylan's largest U.S. consumer healthcare brand and is part of a growing portfolio of over-the-counter products in the U.S. Mylan is committed to providing access to the medications that patients need, whether they are in front of or behind the pharmacy counter. We look forward to serving this loyal customer base and supporting this well-known brand."
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We market a growing portfolio of approximately 7,500 products around the world, including antiretroviral therapies on which approximately 50% of people being treated for HIV/AIDS in the developing world depend. We market our products in more than 165 countries and territories. We are one of the world's largest producers of active pharmaceutical ingredients. Every member of our more than 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at mylan.com.
SOURCE Mylan N.V.
For further information: Nina Devlin (Media), 724.514.1968; Kris King (Investors), 724.514.1813